196 related articles for article (PubMed ID: 38084790)
21. T cell-mediated antitumor immune response eliminates skin tumors induced by mouse papillomavirus, MmuPV1.
Joh J; Chilton PM; Wilcher SA; Zahin M; Park J; Proctor ML; Ghim SJ; Jenson AB
Exp Mol Pathol; 2017 Oct; 103(2):181-190. PubMed ID: 28939161
[TBL] [Abstract][Full Text] [Related]
22. Human papillomavirus types causing recurrent respiratory papillomatosis in Zimbabwe.
Matinhira N; Soko ND; Bandason T; Jenson RG; Dzongodza T; von Buchwald C; Chidziva C
Int J Pediatr Otorhinolaryngol; 2019 Jan; 116():147-152. PubMed ID: 30554686
[TBL] [Abstract][Full Text] [Related]
23. Mouse papillomavirus type 1 (MmuPV1) DNA is frequently integrated in benign tumors by microhomology-mediated end-joining.
Yu L; Majerciak V; Xue XY; Uberoi A; Lobanov A; Chen X; Cam M; Hughes SH; Lambert PF; Zheng ZM
PLoS Pathog; 2021 Aug; 17(8):e1009812. PubMed ID: 34343212
[TBL] [Abstract][Full Text] [Related]
24. A novel lineage-tracing mouse model for studying early MmuPV1 infections.
Yilmaz V; Louca P; Potamiti L; Panayiotidis M; Strati K
Elife; 2022 May; 11():. PubMed ID: 35533001
[TBL] [Abstract][Full Text] [Related]
25. Mus musculus papillomavirus 1 is a key driver of skin cancer development upon immunosuppression.
Dorfer S; Strasser K; Schröckenfuchs G; Bonelli M; Bauer W; Kittler H; Cataisson C; Fischer MB; Lichtenberger BM; Handisurya A
Am J Transplant; 2021 Feb; 21(2):525-539. PubMed ID: 33063442
[TBL] [Abstract][Full Text] [Related]
26. Mouse papillomavirus infections spread to cutaneous sites with progression to malignancy.
Cladel NM; Budgeon LR; Cooper TK; Balogh KK; Christensen ND; Myers R; Majerciak V; Gotte D; Zheng ZM; Hu J
J Gen Virol; 2017 Oct; 98(10):2520-2529. PubMed ID: 28942760
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of Topically Administered Dihydroartemisinin in Treating Papillomavirus-Induced Anogenital Dysplasia in Preclinical Mouse Models.
Gunder LC; Blaine-Sauer S; Johnson HR; Shin MK; Auyeung AS; Zhang W; Leverson GE; Ward-Shaw ET; King RE; McGregor SM; Matkowskyj KA; Lambert PF; Carchman EH
Viruses; 2022 Jul; 14(8):. PubMed ID: 35893697
[TBL] [Abstract][Full Text] [Related]
28. Infectivity of murine papillomavirus in the surgical byproducts of treated tail warts.
Best SR; Esquivel D; Mellinger-Pilgrim R; Roden RBS; Pitman MJ
Laryngoscope; 2020 Mar; 130(3):712-717. PubMed ID: 31041820
[TBL] [Abstract][Full Text] [Related]
29. Concurrent oral human papilloma virus infection in patients with recurrent respiratory papillomatosis: a preliminary study.
Born H; Ruiz R; Verma A; Taliercio S; Achlatis S; Pitman M; Gandonu S; Bing R; Amin MR; Branski RC
Laryngoscope; 2014 Dec; 124(12):2785-90. PubMed ID: 25059492
[TBL] [Abstract][Full Text] [Related]
30. Prevalence and clinical implications of low-risk human papillomavirus among patients with recurrent respiratory papillomatosis in Rio de Janeiro, Brazil.
Figueiredo MC; Justino MC; Delmonico L; Silvestre RT; de Castro TL; Dos Santos Moreira A; Macedo JMB; da Costa Carvalho MDG; Scherrer L; de Medeiros Lima DJM; Alves G; Ornellas MH
Auris Nasus Larynx; 2019 Aug; 46(4):570-575. PubMed ID: 30581074
[TBL] [Abstract][Full Text] [Related]
31. [Prevalence of human papillomavirus infection in squamous cell carcinoma of the oral cavity, oropharynx and larynx].
Villagómez-Ortíz VJ; Paz-Delgadillo DE; Marino-Martínez I; Ceseñas-Falcón LÁ; Sandoval-de la Fuente A; Reyes-Escobedo A
Cir Cir; 2016; 84(5):363-8. PubMed ID: 27032466
[TBL] [Abstract][Full Text] [Related]
32. Role of E6 in Maintaining the Basal Cell Reservoir during Productive Papillomavirus Infection.
Saunders-Wood T; Egawa N; Zheng K; Giaretta A; Griffin HM; Doorbar J
J Virol; 2022 Mar; 96(5):e0118121. PubMed ID: 35019722
[TBL] [Abstract][Full Text] [Related]
33. Insights into the Role of Innate Immunity in Cervicovaginal Papillomavirus Infection from Studies Using Gene-Deficient Mice.
Scagnolari C; Cannella F; Pierangeli A; Mellinger Pilgrim R; Antonelli G; Rowley D; Wong M; Best S; Xing D; Roden RBS; Viscidi R
J Virol; 2020 Jun; 94(12):. PubMed ID: 32295905
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of Cellular MEK/ERK Signaling Suppresses Murine Papillomavirus Type 1 Replicative Activities and Promotes Tumor Regression.
Luna AJ; Young JM; Sterk RT; Bondu V; Schultz FA; Kusewitt DF; Kang H; Ozbun MA
bioRxiv; 2023 Apr; ():. PubMed ID: 36993217
[TBL] [Abstract][Full Text] [Related]
35. The human papillomavirus 16 E5 gene potentiates MmuPV1-Dependent pathogenesis.
Torres AD; Spurgeon ME; Bilger A; Blaine-Sauer S; Uberoi A; Buehler D; McGregor SM; Ward-Shaw E; Lambert PF
Virology; 2020 Feb; 541():1-12. PubMed ID: 31826841
[TBL] [Abstract][Full Text] [Related]
36. Laryngeal distribution of recurrent respiratory papillomatosis in a previously untreated cohort.
Benedict PA; Ruiz R; Yoo M; Verma A; Ahmed OH; Wang B; Dion GR; Voigt A; Merati A; Rosen CA; Amin MR; Branski RC
Laryngoscope; 2018 Jan; 128(1):138-143. PubMed ID: 28714564
[TBL] [Abstract][Full Text] [Related]
37. Mouse papillomavirus MmuPV1 infects oral mucosa and preferentially targets the base of the tongue.
Cladel NM; Budgeon LR; Balogh KK; Cooper TK; Hu J; Christensen ND
Virology; 2016 Jan; 488():73-80. PubMed ID: 26609937
[TBL] [Abstract][Full Text] [Related]
38. Role of Ultraviolet Radiation in Papillomavirus-Induced Disease.
Uberoi A; Yoshida S; Frazer IH; Pitot HC; Lambert PF
PLoS Pathog; 2016 May; 12(5):e1005664. PubMed ID: 27244228
[TBL] [Abstract][Full Text] [Related]
39. Immune Responses in Oral Papillomavirus Clearance in the MmuPV1 Mouse Model.
Brendle SA; Li JJ; Walter V; Schell TD; Kozak M; Balogh KK; Lu S; Christensen ND; Zhu Y; El-Bayoumy K; Hu J
Pathogens; 2023 Dec; 12(12):. PubMed ID: 38133335
[TBL] [Abstract][Full Text] [Related]
40. Immunity to commensal papillomaviruses protects against skin cancer.
Strickley JD; Messerschmidt JL; Awad ME; Li T; Hasegawa T; Ha DT; Nabeta HW; Bevins PA; Ngo KH; Asgari MM; Nazarian RM; Neel VA; Jenson AB; Joh J; Demehri S
Nature; 2019 Nov; 575(7783):519-522. PubMed ID: 31666702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
